Keto Biotech (300858): Optimizing the business structure, steady revenue growth, and focusing on the progress of probiotics sector expansion

china great wall securitiesNov 28, 2024 00:00

Keto Biotech (300858): Probiotics are growing rapidly, animal and plant microecological preparations release new production capacity

Aug 28, 2024 00:00

Cotuo Biotech (300858): The effects of strategic transformation showed a high increase in deduction of non-profit

Aug 21, 2024 18:56

Keto Biotech (300858): Three sub-brands unveiled at new product launch conference, probiotics core business boom can be expected

Jun 7, 2024 00:00

Ketuo Biotech (300858) Company In-depth Research Report: Equity Incentives+Production Capacity Landed, Probiotics Leading the Way and Set Sail

May 21, 2024 00:00

Cotobiotics (300858): Probiotics business performed well in 2023, increasing revenue share to 64%

May 2, 2024 00:00

Cotuobiology (300858): Probiotics business performance is outstanding, accelerating strategic transformation

Apr 25, 2024 16:01

Cotuo Biotech (300858): The first probiotic strain accelerates transformation during domestic substitution

Apr 23, 2024 16:02

Dongwu Securities released a research report on April 23 stating that it gave Koto Biotech (300858.SZ) a purchase rating. The main reasons for the rating include: 1) the rapid expansion of downstream demand driving the growth of the upstream market; 2) hi

Zhitong FinanceApr 23, 2024 15:45

Cotuobiology (300858): Probiotics promote business structure upgrading, equity incentives highlight confidence in development

Feb 22, 2024 00:00

Ketuo Biotech (300858): Performance pains, hope for an inflection point, new director to take office and be revitalized

Dec 3, 2023 00:00

Ketuo Biotech (300858) 2023 Third Quarter Report Performance Review: Waiting for an inflection point in performance during the painful period of transformation

SoochowOct 27, 2023 16:42

Ketuo Biotech (300858): Performance is stable and needs to be expanded

Southwest SecuritiesOct 24, 2023 00:00

Cotto Biotech (300858) 2023 semi-annual performance review: marginal improvement in compounding business probiotic business falls short of expectations

東吳證券Aug 4, 2023 21:07

Coto Biotech (300858): Probiotics have become the company's largest share of the business

中金公司Aug 2, 2023 10:02

Cotuo Biotech (300858) Company Review Report: Maintaining a high growth in the edible probiotic business led to a year-on-year increase in the company's profitability

方正證券Aug 1, 2023 00:00

Strong R&D strength of Koto Biotech (300858) drives domestic probiotics to set sail

財通證券May 25, 2023 14:32

Koto Biotech (300858): Poor compound probiotic growth performance fell short of expectations

東吳證券Apr 23, 2023 00:00

Koto Biotech (300858): Performance during the transition period was dragged down by compounding, probiotics maintained high growth and gradually dominated the company's growth

方正證券Apr 20, 2023 18:24

Keto Biotech (300858): 1Q23 probiotic business is steady and compounding business is under pressure

中金公司Apr 19, 2023 00:00